$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000161883522000166 Filed on August 12, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$6.371M	$6.034M	$4.251M
YoY Change	272.14%	224.93%	284.71%
Cost Of Revenue	$1.680M	$1.285M	$1.066M
YoY Change	75.92%	53.16%	110.67%
Gross Profit	$4.691M	$4.749M	$3.185M
YoY Change	519.68%	366.5%	431.72%
Gross Profit Margin	73.63%	78.7%	74.92%
Selling, General & Admin	$18.21M	$21.42M	$21.72M
YoY Change	-48.6%	-36.34%	-43.15%
% of Gross Profit	388.15%	451.13%	682.04%
Research & Development	$5.207M	$7.744M	$10.39M
YoY Change	-40.16%	-8.97%	43.09%
% of Gross Profit	111.0%	163.07%	326.25%
Depreciation & Amortization	$250.0K	$250.0K	$265.0K
YoY Change	-6.72%	-7.41%	32.5%
% of Gross Profit	5.33%	5.26%	8.32%
Operating Expenses	$23.42M	$29.17M	$32.11M
YoY Change	-48.06%	-32.17%	-30.15%
Operating Profit	-$18.72M	-$24.42M	-$28.93M
YoY Change	-56.83%	-40.65%	-35.53%
Interest Expense	$108.7M	-$101.1M	$523.0K
YoY Change	-468.38%	-1234.46%	-54.6%
% of Operating Profit
Other Income/Expense, Net	$108.2M	-$101.5M	-$2.956M
YoY Change	-452.67%	-1413.94%	130.94%
Pretax Income	$89.52M	-$126.0M	-$31.89M
YoY Change	-220.87%	276.97%	-30.91%
Income Tax	$13.00K	$20.00K	$3.000K
% Of Pretax Income	0.01%
Net Earnings	$89.51M	-$126.0M	-$31.89M
YoY Change	-220.85%	276.89%	-30.91%
Net Earnings / Revenue	1404.9%	-2087.84%	-750.13%
Basic Earnings Per Share	$1.09	-$4.57	-$2.88
Diluted Earnings Per Share	-$0.04	-$4.57	-$2.88
COMMON SHARES
Basic Shares Outstanding	85.46M shares	27.13M shares	11.09M shares
Diluted Shares Outstanding	555.2M shares	27.13M shares	11.09M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.749M	$19.89M	$2.761M
YoY Change	-47.84%	-57.68%	-93.91%
Cash & Equivalents	$7.749M	$19.89M	$2.761M
Short-Term Investments
Other Short-Term Assets	$6.101M	$8.772M	$8.797M
YoY Change	-76.46%	-74.75%	-61.92%
Inventory	$5.179M	$6.133M	$7.161M
Prepaid Expenses
Receivables	$12.76M	$7.304M	$4.416M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$31.79M	$41.91M	$21.36M
YoY Change	-42.09%	-56.18%	-73.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.276M	$5.306M	$5.518M
YoY Change	-25.88%	-10.82%	-1.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.111M	$1.224M	$2.706M
YoY Change	12.11%	19.88%	164.77%
Total Long-Term Assets	$10.49M	$11.57M	$13.21M
YoY Change	-16.23%	-11.82%	0.62%
TOTAL ASSETS
Total Short-Term Assets	$31.79M	$41.91M	$21.36M
Total Long-Term Assets	$10.49M	$11.57M	$13.21M
Total Assets	$42.28M	$53.47M	$34.57M
YoY Change	-37.29%	-50.83%	-63.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$14.54M	$15.39M	$14.04M
YoY Change	114.25%	99.75%	115.98%
Accrued Expenses	$5.505M	$6.918M	$9.749M
YoY Change	-38.98%	-7.7%	8.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$4.054M	$267.0K
YoY Change			-99.5%
Long-Term Debt Due	$77.53M	$115.5M	$113.8M
YoY Change	12.81%	160.57%
Total Short-Term Liabilities	$116.7M	$265.6M	$154.5M
YoY Change	23.26%	288.69%	104.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$0.00	$3.913M	$4.059M
YoY Change	-100.0%	-25.76%	-28.79%
Total Long-Term Liabilities	$0.00	$3.913M	$4.059M
YoY Change	-100.0%	-87.56%	-87.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$116.7M	$265.6M	$154.5M
Total Long-Term Liabilities	$0.00	$3.913M	$4.059M
Total Liabilities	$120.3M	$269.5M	$158.5M
YoY Change	-4.69%	170.05%	48.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$930.4M	-$1.000B	-$892.6M
YoY Change	14.99%	36.04%	27.22%
Common Stock	$815.4M	$802.3M	$759.2M
YoY Change	9.41%	7.83%	10.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$78.04M	-$216.0M	-$128.1M
YoY Change
Total Liabilities & Shareholders Equity	$42.28M	$53.47M	$34.57M
YoY Change	-37.29%	-50.83%	-63.01%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	$89.51M	-$126.0M	-$31.89M
YoY Change	-220.85%	276.89%	-30.91%
Depreciation, Depletion And Amortization	$250.0K	$250.0K	$265.0K
YoY Change	-6.72%	-7.41%	32.5%
Cash From Operating Activities	-$16.30M	-$26.66M	-$20.92M
YoY Change	-56.38%	-50.24%	-39.29%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	-$170.0K	$66.00K
YoY Change	-88.27%	-87.21%	-93.1%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$70.00K	-$170.0K	-$66.00K
YoY Change	-88.27%	-87.21%	-90.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.946M	41.36M	$15.13M
YoY Change	24562.5%	-21.66%	-45.98%
NET CHANGE
Cash From Operating Activities	-16.30M	-26.66M	-$20.92M
Cash From Investing Activities	-70.00K	-170.0K	-$66.00K
Cash From Financing Activities	3.946M	41.36M	$15.13M
Net Change In Cash	-12.42M	14.53M	-$5.856M
YoY Change	-67.26%	-791.11%	-18.19%
FREE CASH FLOW
Cash From Operating Activities	-$16.30M	-$26.66M	-$20.92M
Capital Expenditures	-$70.00K	-$170.0K	$66.00K
Free Cash Flow	-$16.23M	-$26.49M	-$20.99M
YoY Change	-55.86%	-49.3%	-40.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2022Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021Q2	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2021Q2	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q2	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Entity File Number EntityFileNumber	001-36754
	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8527075
	dei	Entity Address Address Line1 EntityAddressAddressLine1	12400 High Bluff Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	550-1900
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5037000	usd
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	85459214	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19885000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7732000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1581000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	5056000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7304000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6449000	usd
CY2022Q2	evfm	Inventories Current InventoriesCurrent	5946000	usd
CY2021Q4	evfm	Inventories Current InventoriesCurrent	7674000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7191000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3229000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	41907000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	30140000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5306000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5774000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5395000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1224000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1203000	usd
CY2022Q2	us-gaap	Assets Assets	53474000	usd
CY2021Q4	us-gaap	Assets Assets	42512000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	15387000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10316000	usd
CY2022Q2	us-gaap	Notes Payable Current NotesPayableCurrent	4054000	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6918000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8370000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5468000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4653000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2317000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2332000	usd
CY2022Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	113538000	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	202000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2419000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2864000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	265556000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	137663000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3913000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4424000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	269469000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	142087000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.0001
CY2022Q2	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	79057255	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	79057255	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10833308	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10833308	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	802266000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	751275000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1595000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5089000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1019864000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-860680000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-215995000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-104315000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53474000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42512000	usd
CY2022Q2	us-gaap	Revenues Revenues	6034000	usd
CY2021Q2	us-gaap	Revenues Revenues	1857000	usd
	us-gaap	Revenues Revenues	10285000	usd
	us-gaap	Revenues Revenues	2962000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1285000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	839000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2351000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1345000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7744000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8507000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18135000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15769000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12298000	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	27237000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	25003000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	57762000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9126000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6416000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18144000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14100000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	30453000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	42999000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	63633000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	88976000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-24419000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-41142000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-53348000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-86014000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	4000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	11000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-415000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1186000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-886000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2331000	usd
CY2022Q2	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	71150000	usd
CY2021Q2	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	0	usd
	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	72002000	usd
	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	0	usd
CY2022Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-29980000	usd
CY2021Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	8910000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-31614000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	8768000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-101541000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7728000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-104497000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6448000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-124072000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-124072000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-125960000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33414000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-157845000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-79566000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-125980000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-33426000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157868000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-79577000	usd
CY2022Q2	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	-1908000	usd
CY2021Q2	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	0	usd
	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	-1827000	usd
	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	0	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-11.52
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-33426000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33426000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-156041000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-156041000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-79577000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-79577000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.57
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.57
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.01
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-11.52
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27130378	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27130378	shares
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-161362000	usd
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8344571	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8344571	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19155923	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19155923	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6908375	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6908375	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-125980000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-33426000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157868000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-79577000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-3675000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	0	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-3494000	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	0	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-129655000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33426000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-79577000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-104315000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5400000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	708000	usd
CY2022Q1	evfm	Temporary Equity Convertible Preferred Stock Deemed Dividends TemporaryEquityConvertiblePreferredStockDeemedDividends	81000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	181000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	828000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1067000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-31888000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-128100000	usd
CY2022Q2	evfm	Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions	20000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	858000	usd
CY2022Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	18000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	543000	usd
CY2022Q2	evfm	Stock Issued During Period Value Exchange Transaction StockIssuedDuringPeriodValueExchangeTransaction	2339000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-3675000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	231000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1081000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-125980000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-215995000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1347000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	27709000	usd
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3464000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-46151000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-13638000	usd
CY2021Q2	evfm	Stock Issued During Period Value Employee Stock Purchase Plans And Exercise Of Stock Options StockIssuedDuringPeriodValueEmployeeStockPurchasePlansAndExerciseOfStockOptions	196000	usd
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	300000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2993000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-33426000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	8964000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-157868000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-79577000	usd
	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	72002000	usd
	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	0	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-31614000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	8768000	usd
	evfm	Financial Instrument Modification Expense FinancialInstrumentModificationExpense	1056000	usd
	evfm	Financial Instrument Modification Expense FinancialInstrumentModificationExpense	0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2148000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6457000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	515000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	470000	usd
	us-gaap	Lease Cost LeaseCost	301000	usd
	us-gaap	Lease Cost LeaseCost	676000	usd
	us-gaap	Interest Expense InterestExpense	1055000	usd
	us-gaap	Interest Expense InterestExpense	1647000	usd
	evfm	Financial Instrument Expense Noncash FinancialInstrumentExpenseNoncash	514000	usd
	evfm	Financial Instrument Expense Noncash FinancialInstrumentExpenseNoncash	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	855000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2041000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1542000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2725000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2749000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2473000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4728000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2821000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1929000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4005000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	816000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2242000	usd
	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-469000	usd
	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-643000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47579000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88035000	usd
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	usd
	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	236000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2289000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-236000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2039000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	20922000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	49000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	20000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	196000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5892000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	859000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	660000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	18000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	307000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	56493000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80811000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8678000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-9263000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13588000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72251000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22266000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62988000	usd
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	563000	usd
	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	75000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	189000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	203000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1187000	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	usd
	evfm	Temporary Equity Value Exchange Of Convertible Securities TemporaryEquityValueExchangeOfConvertibleSecurities	1616000	usd
	evfm	Temporary Equity Value Exchange Of Convertible Securities TemporaryEquityValueExchangeOfConvertibleSecurities	0	usd
	us-gaap	Stock Issued1 StockIssued1	858000	usd
	us-gaap	Stock Issued1 StockIssued1	0	usd
	evfm	Proceeds From Issuance Of Notes And Warrants ProceedsFromIssuanceOfNotesAndWarrants	10000000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19900000	usd
CY2022Q2	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	-223600000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1000000000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46982000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ignificant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items, the trade accounts receivable credit loss reserve estimate, the discount rate used in estimating the fair value of the lease right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use (ROU) assets and lease liabilities, the assumptions used in estimating the fair value of notes, derivative liabilities, convertible preferred stock, warrants and purchase rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, inventory reserves, clinical trial accruals, the assumptions used in estimating the fair value of stock-based compensation expense and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards (performance-based RSAs). These assumptions are more fully described in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id26d1f62c83e4ef893ef4a4b74095c18_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3- Revenue</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id26d1f62c83e4ef893ef4a4b74095c18_52" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 4- Debt</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id26d1f62c83e4ef893ef4a4b74095c18_61" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6- Fair Value of Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id26d1f62c83e4ef893ef4a4b74095c18_64" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7- Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#id26d1f62c83e4ef893ef4a4b74095c18_70" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 9- Stock-based Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of June 30, 2022, based on the evaluation of these factors, the Company did not record an allowance for doubtful accounts. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phexxi is distributed primarily through three major distributors and a mail-order pharmacy, who receive service fees calculated as a percentage of the gross sales, and fee per units shipped, respectively. These entities are not obligated to purchase any set number of units and distribute Phexxi on demand as orders are received. For the three and six months ended June 30, 2022, the Company’s three largest customers combined made up approximately 72% and 71% of its gross product sales, respectively. For the three and six months ended June 30, 2021, the Company’s three largest customers combined made up approximately 83% and 85% of its gross product sales, respectively. As of June 30, 2022 and December 31, 2021, the Company's three largest customers combined made up 78% and 75%, respectively, of its trade accounts receivable balance.</span></div>
CY2020Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19885000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	1581000	usd
CY2021Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	15206000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22266000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62988000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	125495884	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6546838	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1000400	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.88
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1037885	shares
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.1805
CY2022Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q2	evfm	Exchange Agreement Number Of Common Shares To Be Redeemed ExchangeAgreementNumberOfCommonSharesToBeRedeemed	533333	shares
CY2022Q2	evfm	Exchange Agreement Number Of Common Shares To Be Issued To Investors ExchangeAgreementNumberOfCommonSharesToBeIssuedToInvestors	208333	shares
CY2022Q2	evfm	Exchange Agreement Number Of Common Shares To Be Redeemed ExchangeAgreementNumberOfCommonSharesToBeRedeemed	533333	shares
CY2022Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	14043000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	11176000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1179000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1177000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	574000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	574000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1783000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1712000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3776000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5629000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	6133000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7915000	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	300000	usd
CY2021Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	200000	usd
CY2022Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	200000	usd
CY2022Q2	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	4569000	usd
CY2021Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	5294000	usd
CY2022Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1140000	usd
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1997000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	831000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	550000	usd
CY2022Q2	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	0	usd
CY2021Q4	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	201000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	378000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	328000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6918000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8370000	usd
	evfm	Lessee Operating Lease Number Of Vehicles Leased LesseeOperatingLeaseNumberOfVehiclesLeased	75	vehicle
CY2019Q4	evfm	Office Square Footage OfficeSquareFootage	24474	sqft
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q2	evfm	Office Square Footage OfficeSquareFootage	8816	sqft
CY2022Q2	evfm	Lessee Operating Sublease Rentable Area LesseeOperatingSubleaseRentableArea	16637	sqft
CY2022Q2	evfm	Lessee Operating Sublease Monthly Rent LesseeOperatingSubleaseMonthlyRent	87000	usd
CY2022Q2	evfm	Lessee Operating Sublease Annual Increase LesseeOperatingSubleaseAnnualIncrease	0.035
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	603000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	584000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M8D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M29D
CY2022Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1301000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2440000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2311000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1506000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7558000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1328000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	6230000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1289000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1139000	usd
	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	usd
CY2022Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	usd
CY2021Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	1900000	usd
	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	3000000	usd
CY2022Q2	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	123120348	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.58
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	833333	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.4765
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	42870152	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	72860769	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.75
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	123120348	shares
CY2022Q2	evfm	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	123120348	shares
CY2022Q2	evfm	Common Stock Reserved For The Conversion Of Convertible Notes CommonStockReservedForTheConversionOfConvertibleNotes	76115602	shares
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	200423095	shares
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1081000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2993000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2148000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6457000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	40000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	257718	shares

Files In Submission

Name	View Source	Status
0001618835-22-000166-index-headers.html	Edgar Link	pending
0001618835-22-000166-index.html	Edgar Link	pending
0001618835-22-000166.txt	Edgar Link	pending
0001618835-22-000166-xbrl.zip	Edgar Link	pending
evfm-20220630.htm	Edgar Link	pending
evfm-20220630.xsd	Edgar Link	pending
evfm-6302022xex311.htm	Edgar Link	pending
evfm-6302022xex312.htm	Edgar Link	pending
evfm-6302022xex321.htm	Edgar Link	pending
exhibit105.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
evfm-20220630_cal.xml	Edgar Link	unprocessable
evfm-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
evfm-20220630_lab.xml	Edgar Link	unprocessable
evfm-20220630_pre.xml	Edgar Link	unprocessable
evfm-20220630_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2022 Q3 Form 10-Q Financial Statement

#000161883522000166 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2022 Q3 Form 10-Q Financial Statement

#000161883522000166 Filed on August 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm